March 14, 2019 / 1:13 PM / a month ago

U.S. patent court rejects Alvogen's challenge for Celgene's Revlimid

March 14 (Reuters) - A U.S. administrative court on Thursday rejected a filing by Alvogen Pine Brook Llc for a review challenging patents on Celgene Corp’s blockbuster myeloma drug Revlimid.

The Patent Trial and Appeal Board, a court run by the U.S. patent office, said it was denying Alvogen’s petition for an inter-partes review on the patents of the drug.

Drugmaker Bristol-Myers Squibb Co in January said it would buy Celgene Corporation for about $74 billion, to expand its pipeline of cancer drugs.

Revlimid, Celgene’s cancer drug that brought in sales of $2.55 billion in the fourth quarter, faces loss of exclusivity beginning 2022 in the United States.

Reporting by Manas Mishra in Bengaluru; Editing by James Emmanuel

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below